Wednesday, November 14, 2018 11:24:23 AM
In the primary endpoint responder analysis in the modified Intent to Treat, or mITT population, 74% of NeoCart patients were responders at one year versus 62% of microfracture patients, missing statistical significance by just one or two microfracture responders. However, 62% of our NeoCart patients were statistically significant responders at six months versus 46% of microfracture patients. We also demonstrated statistical superiority in the dual threshold responder analysis on a variety of other covariate analyses such as in patients with BMI greater than 28 and then in lesions greater than 2.2 square centimeters, which we believe represent the broader patient populations treated by surgeons.
The underlying IKDC function and KOOS pain outcome data utilized conduct the responder analysis and other efficacy analyses were prospectively defined and collected and can be used to demonstrate efficacies in current FDA standards. On those FDA standards, NeoCart demonstrated both clinically meaningful improvements in pain and function from baseline versus microfracture and statistically significant improvements in both KOOS and IKDC endpoints as compared to baseline at one and two years.
These early and sustained improvements in pain and function results in meaningful clinical outcomes for patients. We also believe them to be compelling when compared to other products either in development or on the market. Based on the conduct of the NeoCart Phase III trial, the inclusion exclusion criteria and resulting patient demographics, our surgeons have remarked how meaningfully different than NeoCart results are when evaluating patients during follow-ups.
So why do we miss our endpoint? NeoCart performed well in the trial better than the statistical plan and better on virtually every endpoint analyzed. However, the microfracture control arms simply showed a treatment effect even greater than expected in the statistical plan. This is not a normal placebo effect whether it is well established that in the limited patient population with strict rehabilitation protocols, active controls or microfracture patients can do well for some period of time.
https://seekingalpha.com/article/4220807-histogenics-hsgx-ceo-adam-gridley-q3-2018-results-earnings-call-transcript?page=2
Recent OCGN News
- Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 10:30:50 AM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 • GlobeNewswire Inc. • 03/13/2024 12:00:54 PM
- Ocugen to Present at Investing in Cures Summit • GlobeNewswire Inc. • 03/06/2024 12:30:09 PM
- Ocugen Clinical Showcase Webcast Now Available • GlobeNewswire Inc. • 02/28/2024 01:00:26 PM
- Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit • GlobeNewswire Inc. • 02/26/2024 01:30:13 PM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Ocugen to Present at 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 04:22:29 PM
- Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 • GlobeNewswire Inc. • 02/14/2024 12:30:49 PM
- Ocugen to Present at Pharma Market Research Conference • GlobeNewswire Inc. • 01/31/2024 01:00:12 PM
- Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board • GlobeNewswire Inc. • 01/16/2024 12:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:05:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:47:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:47:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:04:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 08:09:27 PM
- Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design • GlobeNewswire Inc. • 12/21/2023 11:30:09 AM
- Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations • GlobeNewswire Inc. • 12/19/2023 12:30:00 PM
- Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 12/13/2023 12:30:14 PM
- Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference • GlobeNewswire Inc. • 11/29/2023 12:30:12 PM
- Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease • GlobeNewswire Inc. • 11/10/2023 12:30:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:02:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:02:54 PM
- Ocugen Provides Business Update with Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 11:30:00 AM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM